首页> 外文期刊>Toxicology in vitro: an international journal published in association with BIBRA >Development of an in vitro system and model-based translational framework to assess haemolysis risk following intravenous abuse of medications containing polyethylene oxide
【24h】

Development of an in vitro system and model-based translational framework to assess haemolysis risk following intravenous abuse of medications containing polyethylene oxide

机译:在静脉内滥用含聚乙烯氧化物的药物后评估溶血风险的体外系统和基于模型的平移框架的发展

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Multiple cases of potentially life-threatening thrombotic microangiopathy (TMA) have resulted from intravenous abuse of medications containing polyethylene oxide (PEO), most often Opana ER (oxymorphone hydrochloride extended release). No validated models are available to assess the risk of TMA with different formulations and extraction methods following intravenous abuse. We have developed an in vitro system that involves passing pooled blood containing the excipient of interest through a syringe needle and assessing haemolysis via haemoglobin release. Haemolysis is induced by high shear stress caused by the flow of blood containing PEO through a narrow-bore syringe needle, recapitulating the mechanism in small blood vessels. Using the in vitro system, we demonstrate that high-molecular-weight PEO ( > 1 MDa) induces haemolysis in a concentration-dependent manner under flowing but not static conditions. We use data from the in vitro system and published in vivo data to predict the time course of the haemolytic response in vivo via a pharmacometric model. The in vitro system is a novel method for investigating factors influencing PEO-induced haemolysis. In combination with our model-based translational framework, the in vitro system allows straightforward assessment of the haemolytic potential of PEO-containing medications, and may find application in gauging TMA risk following intravenous abuse.
机译:潜在危及危及血栓性微臂病变(TMA)的多种病例是由于静脉内滥用含有聚环氧丙烷(PEO)的药物,最常是OpanaER(盐酸盐次盐酸盐延长释放)。没有经过验证的型号可用于评估TMA具有不同配方和提取方法的TMA的风险。我们开发了一种体外系统,涉及通过注射器针通过注射器针和通过血红蛋白释放评估溶血性的含有感兴趣的血液。通过通过窄孔注射针含有PEO的血液流动引起的高剪切应力引起溶血溶解,重新携带小血管中的机制。使用体外系统,我们证明了高分子量PEO(> 1MDA)以流动但不是静态条件诱导浓度依赖性的方式诱导溶血。我们使用来自体外系统的数据,并在体内数据发布,以通过药学模型预测体内血液解反应的时间过程。体外系统是一种研究影响PEO诱导的溶血的因素的新方法。与我们的模型的平移框架相结合,体外体系允许直接评估含有人的药物药物的溶血潜力,并且可以在静脉内滥用之后衡量TMA风险的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号